MT Newswires5d agoneutral
BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $620 From $600News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
106last 24h
3125last 7d
511● bullish (7d)
311● bearish (7d)
227publishers
MT Newswires5d agoneutral
TD Cowen Adjusts Price Target on Vertex Pharmaceuticals to $575 From $550MT Newswires5d agoneutral
JPMorgan Adjusts Price Target on Vertex Pharmaceuticals to $570 From $560Investor's Business Daily6d agoneutral
Vertex Yo-Yos On Mixed Third-Quarter Report, Light Guidance HikeInvestor's Business Daily6d agobullish
Vertex Continues Its Buy-Zone Run After Hiking 2026 Sales GuidanceSimply Wall St.8d agoneutral
Vertex Pharmaceuticals (VRTX) Stock May Still Have Value Following A 190% RunSimply Wall St.8d agoneutral
Is Vertex Pharmaceuticals (VRTX) Fully Priced Following Its Kidney Data Update?MT Newswires9d agoneutral
Vertex Pharmaceuticals Says UK Approves Casgevy for Children Aged 5 and Older